Technical Analysis for MGX - Metagenomi, Inc.

Grade Last Price % Change Price Change
F 2.11 7.11% 0.14
MGX closed up 7.11 percent on Friday, November 1, 2024, on 55 percent of normal volume.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Down Up

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze + Upper Band Touch Range Contraction 0.00%
Above Upper BB Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Fell Below 20 DMA Bearish 7.11%
Bollinger Band Squeeze Range Contraction 7.11%
BB Squeeze + Upper Band Touch Range Contraction 7.11%
Upper Bollinger Band Touch Strength 7.11%
20 DMA Support Bullish 0.48%

   Recent Intraday Alerts

Alert Time
Upper Bollinger Band Resistance about 18 hours ago
Rose Above Previous Day's High about 19 hours ago
Rose Above Upper Bollinger Band about 19 hours ago
Up 5% about 19 hours ago
Up 1 ATR about 19 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Metagenomi, Inc. Description

Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Molecular Biology Genetic Engineering CRISPR Genome Editing Biological Engineering Gene Editing Human Cancer

Is MGX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 12.74
52 Week Low 1.85
Average Volume 234,763
200-Day Moving Average 0.00
50-Day Moving Average 2.35
20-Day Moving Average 1.98
10-Day Moving Average 1.98
Average True Range 0.15
RSI (14) 50.25
ADX 25.14
+DI 17.30
-DI 14.60
Chandelier Exit (Long, 3 ATRs) 1.72
Chandelier Exit (Short, 3 ATRs) 2.29
Upper Bollinger Bands 2.08
Lower Bollinger Band 1.87
Percent B (%b) 1.12
BandWidth 10.93
MACD Line -0.09
MACD Signal Line -0.14
MACD Histogram 0.0495
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.38
Resistance 3 (R3) 2.37 2.26 2.34
Resistance 2 (R2) 2.26 2.19 2.27 2.32
Resistance 1 (R1) 2.19 2.15 2.23 2.20 2.31
Pivot Point 2.08 2.08 2.10 2.09 2.08
Support 1 (S1) 2.01 2.01 2.04 2.02 1.91
Support 2 (S2) 1.90 1.97 1.91 1.90
Support 3 (S3) 1.83 1.90 1.88
Support 4 (S4) 1.84